Silibinin
| Code | Size | Price |
|---|
| TAR-T1660-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T1660-100mg | 100mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Silibinin is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.
CAS:
22888-70-6
Formula:
C25H22O10
Molecular Weight:
482.441
Pathway:
Autophagy; Immunology/Inflammation; Metabolism; NF-κb
Purity:
0.9976
SMILES:
COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O
Target:
Reactive Oxygen Species; Autophagy
References
1. Al-Anati L, et al. Mol Nutr Food Res, 2009, 53(4), 460-466.
2. Bhatia N, et al. Cancer Lett, 1999, 147(1-2), 77-84.
3. Hogan FS, et al. J Surg Res 2007, 143(1), 58-65.
4. Sharma G, et al. Anticancer Res, 2003, 23(3B), 2649-2655.